Description

7,9,10,14B-Tetrahydro-2-Chloro-12,13-Dimethoxy-6-Phenylisoquino[2,1-D][1,4]Benzodiazepine is a complex heterocyclic organic compound belonging to the benzodiazepine class, serving as a crucial advanced intermediate in modern pharmaceutical synthesis. Its intricate fused-ring structure makes it a valuable building block for the research and development of novel therapeutic agents, particularly in the central nervous system (CNS) and oncology fields. This high-purity intermediate is essential for pharmaceutical R&D laboratories, contract manufacturing organizations (CMOs), and fine chemical suppliers targeting the synthesis of specialized active pharmaceutical ingredients (APIs).

Application

• Pharmaceutical Intermediate: A key precursor in the multi-step synthesis of novel benzodiazepine-derived active pharmaceutical ingredients (APIs).
• Research & Development: Used in medicinal chemistry for structure-activity relationship (SAR) studies and the development of new drug candidates targeting neurological pathways.
• Contract Synthesis: Supplied to CMOs and CDMOs for the custom manufacturing of complex molecules under cGMP conditions.
• Reference Standard: Serves as a high-purity analytical standard for quality control and method development in pharmaceutical analysis.
• Academic Research: Utilized in university and institutional labs for studying heterocyclic chemistry and benzodiazepine pharmacology.

Basic Information

Product Name	7,9,10,14B-Tetrahydro-2-Chloro-12,13-Dimethoxy-6-Phenylisoquino[2,1-D][1,4]Benzodiazepine
CAS No.	62206-00-2
Molecular Formula	C25H23ClN2O2
Molecular Weight	418.92 g/mol
Synonyms	2-Chloro-12,13-dimethoxy-6-phenylisoquino[2,1-d][1,4]benzodiazepine; 7,9,10,14B-Tetrahydro-2-chloro-12,13-dimethoxy-6-phenylisoquino[2,1-d][1,4]benzodiazepine; Isoquino[2,1-d][1,4]benzodiazepine, 7,9,10,14B-tetrahydro-2-chloro-12,13-dimethoxy-6-phenyl-; 62206-00-2; Benzodiazepine derivative intermediate
EINECS	Contact for details

Quality Control

Our 7,9,10,14B-Tetrahydro-2-Chloro-12,13-Dimethoxy-6-Phenylisoquino[2,1-D][1,4]Benzodiazepine is manufactured under strict quality management systems. Each batch undergoes rigorous analytical testing, including HPLC for purity and identity confirmation via spectroscopic methods, to ensure it meets the stringent requirements for pharmaceutical intermediates. Certificates of Analysis (COA) detailing all specifications and test results are provided with every shipment.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, well-ventilated area at controlled room temperature (typically 15-25°C). Keep away from incompatible materials. For long-term storage, consider an inert atmosphere to preserve stability.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Purity (HPLC)	≥ 98.0%
Loss on Drying	≤ 0.5%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 10 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.